All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Catch up with our live Twitter coverage from the 1st Congress on Myeloproliferative Neoplasms Controversies and Debates.
Combination therapies in myelofibrosis: Latest considerations on toxicity management with JAK inhibitors
The MPN Hub summarizes current clinical advances of JAKi-based combination therapies in myelofibrosis, including key considerations on treatment...
Novel approaches to reduce inflammation in myeloproliferative neoplasms
During MPNCo&D, Fleischman provided an overview of novel ways to reduce inflammation associated with MPN, including N-acetylcysteine, managing the gut microbiome, and optimizing...
Subscribe to get the best content related to MPN delivered to your inbox